|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||61.60 - 61.60|
|52 Week Range||6.16 - 61.60|
|Beta (3Y Monthly)||0.99|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Insider Monkey team has completed processing the quarterly 13F filings for the June quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
Hutchison China MediTech Limited (LON:HCM) shareholders have seen the share price descend 20% over the month. But that...
Investment company FACTORIAL MANAGEMENT Ltd (Current Portfolio) buys Hutchison China Meditech during the 3-months ended 2019Q2, according to the most recent filings of the investment company, FACTORIAL MANAGEMENT Ltd. Continue reading...
NEW YORK , May 17, 2019 /PRNewswire/ -- Deutsche Bank today announced that the presentations from the May 15 th and 16 th Depositary Receipts Virtual Investor Conference ("dbVIC") are now available ...
Biotech company Hutchison China MediTech, known as Chi-Med, has filed for a Hong Kong listing, which four sources close to the matter said could raise up to $500 million. Chi-Med, which is already listed on the London Stock Exchange and the Nasdaq in New York, filed its listing application with the Hong Kong stock exchange on Monday. "We are delighted to announce our proposed Hong Kong listing and global offering of shares," said Simon To, Chairman of Chi-Med, which is 60.2 percent owned by CK Hutchison.
LONDON, Feb. 08, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended December 31, 2018 on Monday, March.
LONDON, Jan. 07, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 37th.
– Global SAVANNAH study of savolitinib / Tagrisso® combination in MET+ EGFRm NSCLC underway. Data presented at ESMO 2018 showed MET-amplification among themost frequent.
Nov 29 (Reuters) - Innovent Biologics Inc: * HAS ENTERED INTO A GLOBAL COLLABORATION AGREEMENT WITH HUTCHISON CHINA MEDITECH LIMITED * UNDER AGREEMENT, UNIT INNOVENT SUZHOU AND HUTCHISON MEDIPHARMA TO ...
Mid-caps stocks, like Hutchison China MediTech Limited (LON:HCM) with a market capitalization of UK£3.2b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or Read More...